RS60718B1 - Jedinjenja i načini upotrebe - Google Patents
Jedinjenja i načini upotrebeInfo
- Publication number
- RS60718B1 RS60718B1 RS20201011A RSP20201011A RS60718B1 RS 60718 B1 RS60718 B1 RS 60718B1 RS 20201011 A RS20201011 A RS 20201011A RS P20201011 A RSP20201011 A RS P20201011A RS 60718 B1 RS60718 B1 RS 60718B1
- Authority
- RS
- Serbia
- Prior art keywords
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN6DE2014 | 2014-01-01 | ||
PCT/US2014/072922 WO2015103355A1 (en) | 2014-01-01 | 2014-12-31 | Compounds and methods of use |
EP14824755.4A EP3089971B1 (en) | 2014-01-01 | 2014-12-31 | Compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
RS60718B1 true RS60718B1 (sr) | 2020-09-30 |
Family
ID=52293317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20201011A RS60718B1 (sr) | 2014-01-01 | 2014-12-31 | Jedinjenja i načini upotrebe |
Country Status (17)
Country | Link |
---|---|
US (4) | US10030004B2 (sr) |
EP (1) | EP3089971B1 (sr) |
JP (2) | JP6474166B2 (sr) |
CN (2) | CN109045032A (sr) |
AU (2) | AU2014373773C1 (sr) |
CA (1) | CA2935392C (sr) |
CY (1) | CY1123290T1 (sr) |
DK (1) | DK3089971T3 (sr) |
ES (1) | ES2813875T3 (sr) |
HR (1) | HRP20201384T1 (sr) |
HU (1) | HUE050761T2 (sr) |
LT (1) | LT3089971T (sr) |
PL (1) | PL3089971T3 (sr) |
PT (1) | PT3089971T (sr) |
RS (1) | RS60718B1 (sr) |
SI (1) | SI3089971T1 (sr) |
WO (1) | WO2015103355A1 (sr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ |
US20210346386A1 (en) | 2018-10-31 | 2021-11-11 | Senju Pharmaceutical Co., Ltd. | Retinal ganglion cell death inhibitor |
US20200199104A1 (en) * | 2018-12-20 | 2020-06-25 | Pfizer Inc. | Novel Polymorphic Forms of a TGFBeta Inhibitor |
CN111116565B (zh) * | 2020-04-01 | 2020-07-14 | 中科利健制药(广州)有限公司 | 2-芳基-4-(4-吡唑氧基)吡啶类化合物、其制备方法、药物组合物与应用 |
US11820773B2 (en) * | 2020-11-24 | 2023-11-21 | Aligos Therapeutics, Inc. | Tricyclic compounds |
WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
CN112843058A (zh) * | 2021-01-27 | 2021-05-28 | 复旦大学附属华山医院 | 烟酰胺类化合物在制备治疗抗脊索肿瘤药物中的应用 |
WO2022229846A1 (en) | 2021-04-29 | 2022-11-03 | Pfizer Inc. | Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor |
CN115353326A (zh) * | 2022-07-27 | 2022-11-18 | 魏玉芝 | 一种反光防车印沥青及其制备方法 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
ES2114662T3 (es) | 1993-08-26 | 1998-06-01 | Ono Pharmaceutical Co | Derivados de la 4-aminopirimidina. |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
WO2000047102A2 (en) | 1999-02-11 | 2000-08-17 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR MODULATING TGF-β SIGNALING |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
AU2001292670A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03005606A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
US20050009815A1 (en) | 2001-11-27 | 2005-01-13 | Devita Robert J. | 4-Aminoquinoline compounds |
US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
US20030225089A1 (en) | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
EP1511738A4 (en) | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
US20040146509A1 (en) | 2002-07-25 | 2004-07-29 | Zhihe Li | Methods for improvement of lung function using TGF-beta inhibitors |
WO2004024159A1 (en) | 2002-09-10 | 2004-03-25 | Scios Inc. | INHIBITORS OF TFGβ |
DE60327443D1 (de) | 2002-09-18 | 2009-06-10 | Pfizer Prod Inc | Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf) |
JP4519657B2 (ja) | 2002-09-18 | 2010-08-04 | ファイザー・プロダクツ・インク | 形質転換成長因子(tgf)阻害剤としての新規なピラゾ−ル化合物 |
AP2005003260A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel triazole compounds as transforming growth factor (TGF) inhibitors. |
EA200500286A1 (ru) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр) |
CN1681805A (zh) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
CA2506978A1 (en) | 2002-11-22 | 2004-06-10 | Scios, Inc. | Method for counteracting a pathologic change in the b-adrenergic pathway |
US20040138188A1 (en) | 2002-11-22 | 2004-07-15 | Higgins Linda S. | Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors |
EP1589960A4 (en) | 2002-12-19 | 2008-09-10 | Scios Inc | TREATMENT OF OBESITY AND RELATED MANIFESTATIONS USING TGF-BETA INHIBITORS |
EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
CA2517720A1 (en) | 2003-03-11 | 2004-09-23 | Pfizer Products Inc. | Pyrazine compounds as transforming growth factor (tgf) inhibitors |
ES2305744T3 (es) | 2003-03-12 | 2008-11-01 | Millennium Pharmaceuticals, Inc. | Derivados de quinazolina como inhibidores e tgf-beta. |
US7223766B2 (en) | 2003-03-28 | 2007-05-29 | Scios, Inc. | Bi-cyclic pyrimidine inhibitors of TGFβ |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US6875781B2 (en) * | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
WO2004112710A2 (en) | 2003-06-17 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
TW200510373A (en) | 2003-07-14 | 2005-03-16 | Neurogen Corp | Substituted quinolin-4-ylamine analogues |
CN1852741A (zh) | 2003-07-16 | 2006-10-25 | Rvx治疗公司 | 下调TGF-β效应的化合物和方法 |
CN1832757A (zh) | 2003-08-01 | 2006-09-13 | 惠氏控股公司 | 表皮生长因子受体激酶抑制剂与细胞毒性剂组合在治疗和抑制癌症中的用途 |
US7232824B2 (en) | 2003-09-30 | 2007-06-19 | Scios, Inc. | Quinazoline derivatives as medicaments |
US7390907B2 (en) | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
ES2576195T3 (es) | 2003-10-15 | 2016-07-06 | National Jewish Health | Cistatina C como antagonista de TGF-B y métodos relacionados con la misma |
WO2005047279A1 (en) | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
AR046324A1 (es) | 2003-11-10 | 2005-11-30 | Merck Sharp & Dohme | Heterociclos nitrogenados de seis miembros aminosustituidos que contienen sustituyentes de quinolina o isoquinolina |
US20070099950A1 (en) | 2003-11-21 | 2007-05-03 | Jongwon Lim | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain |
CN1921864A (zh) * | 2003-12-24 | 2007-02-28 | 西奥斯公司 | 使用TGF-β抑制剂治疗神经胶质瘤 |
WO2005069935A2 (en) | 2004-01-20 | 2005-08-04 | University Of Medicine And Dentistry Of New Jersey | METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF |
US7368445B2 (en) | 2004-03-01 | 2008-05-06 | Eli Lilly And Company | Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms |
EP1794135A1 (en) * | 2004-09-27 | 2007-06-13 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
AU2005288858B2 (en) | 2004-09-30 | 2011-04-21 | Janssen R&D Ireland | HCV inhibiting bi-cyclic pyrimidines |
US7511056B2 (en) | 2004-11-10 | 2009-03-31 | Eli Lilly And Company | TGF-β inhibitors |
WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
WO2006102102A2 (en) | 2005-03-17 | 2006-09-28 | Marshfield Clinic | Tgf-beta modulators and methods for using the same |
US8030318B2 (en) | 2005-03-25 | 2011-10-04 | Tibotec Pharmaceuticals Ltd. | Fused bicyclic inhibitors of HCV |
WO2006105063A1 (en) | 2005-03-25 | 2006-10-05 | Scios Inc. | Heterobicylic inhibitors of tgfbeta |
US20060281763A1 (en) | 2005-03-25 | 2006-12-14 | Axon Jonathan R | Carboxamide inhibitors of TGFbeta |
WO2006119504A2 (en) | 2005-05-04 | 2006-11-09 | Renovis, Inc. | Fused heterocyclic compounds, and compositions and uses thereof |
TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
WO2007145862A2 (en) | 2006-06-05 | 2007-12-21 | Genentech, Inc. | Extending survival of cancer patients with elevated levels of egf or tgf-alpha |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
US9987277B2 (en) | 2006-10-04 | 2018-06-05 | Janssen Sciences Ireland Uc | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C |
WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
MX2009006690A (es) | 2006-12-19 | 2009-07-31 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
GB0702871D0 (en) | 2007-02-14 | 2007-03-28 | Tcp Innovations Ltd | Improved compositions and combinations 1 |
JP2010529193A (ja) | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
WO2009012375A2 (en) * | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
UY31281A1 (es) * | 2007-08-13 | 2009-03-31 | Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones. | |
CN102083800A (zh) | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
CA2744343A1 (en) | 2008-11-19 | 2010-05-27 | Renovis, Inc. | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof |
EP2241565A1 (en) | 2009-01-15 | 2010-10-20 | Universität Leipzig | Aurora kinase inhibitors compounds |
WO2010102267A2 (en) | 2009-03-06 | 2010-09-10 | Ipierian, Inc. | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
US20120101095A1 (en) | 2009-06-22 | 2012-04-26 | Guenter Hoelzemann | Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011054433A1 (en) * | 2009-11-07 | 2011-05-12 | Merck Patent Gmbh | Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors |
AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
ES2528441T3 (es) | 2010-02-22 | 2015-02-10 | Merck Patent Gmbh | Hetarilaminonaftiridinas |
US9073918B2 (en) | 2010-05-20 | 2015-07-07 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 |
MX2012015147A (es) | 2010-06-30 | 2013-05-01 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. |
MX2012015023A (es) * | 2010-06-30 | 2013-04-03 | Fujifilm Corp | Derivado novedoso de nicotinamida o sal del mismo. |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
JP2014501705A (ja) * | 2010-11-01 | 2014-01-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Syk調節剤としてのベンズアミドおよびニコチンアミド |
KR20140022829A (ko) | 2011-03-09 | 2014-02-25 | 메르크 파텐트 게엠베하 | 피리도 [2, 3 - b] 피라진 유도체 및 그 치료적 용도 |
CA2832919A1 (en) * | 2011-04-12 | 2012-10-18 | Ryan C. Holcomb | Compounds, compositions, and therapeutic uses thereof |
WO2012166617A2 (en) * | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
CA2840170A1 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
AU2012312305B2 (en) * | 2011-09-22 | 2016-11-17 | Merck Sharp & Dohme Corp. | Acyclic cyanoethylpyrazoles as janus kinase inhibitors |
US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
WO2013158422A1 (en) | 2012-04-17 | 2013-10-24 | E. I. Du Pont De Nemours And Company | Heterocyclic compounds for controlling invertebrate pests |
WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
EP2863914B1 (en) * | 2012-06-20 | 2018-10-03 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
CN104837525B (zh) * | 2012-12-11 | 2019-04-05 | 皇家飞利浦有限公司 | 用于辅助执行近距离放射治疗的辅助装置 |
EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
JO3336B1 (ar) | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
AR103232A1 (es) | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
WO2018057389A1 (en) | 2016-09-21 | 2018-03-29 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
-
2014
- 2014-12-31 ES ES14824755T patent/ES2813875T3/es active Active
- 2014-12-31 JP JP2016544111A patent/JP6474166B2/ja active Active
- 2014-12-31 WO PCT/US2014/072922 patent/WO2015103355A1/en active Application Filing
- 2014-12-31 CA CA2935392A patent/CA2935392C/en active Active
- 2014-12-31 SI SI201431651T patent/SI3089971T1/sl unknown
- 2014-12-31 DK DK14824755.4T patent/DK3089971T3/da active
- 2014-12-31 CN CN201810955135.1A patent/CN109045032A/zh active Pending
- 2014-12-31 LT LTEP14824755.4T patent/LT3089971T/lt unknown
- 2014-12-31 CN CN201480075343.2A patent/CN106132950B/zh active Active
- 2014-12-31 EP EP14824755.4A patent/EP3089971B1/en active Active
- 2014-12-31 US US15/109,013 patent/US10030004B2/en active Active
- 2014-12-31 RS RS20201011A patent/RS60718B1/sr unknown
- 2014-12-31 PT PT148247554T patent/PT3089971T/pt unknown
- 2014-12-31 AU AU2014373773A patent/AU2014373773C1/en active Active
- 2014-12-31 PL PL14824755T patent/PL3089971T3/pl unknown
- 2014-12-31 HU HUE14824755A patent/HUE050761T2/hu unknown
-
2018
- 2018-03-23 US US15/933,532 patent/US10501436B2/en active Active
- 2018-12-20 AU AU2018282363A patent/AU2018282363B2/en active Active
-
2019
- 2019-01-04 JP JP2019000208A patent/JP2019048899A/ja active Pending
- 2019-10-22 US US16/659,775 patent/US11053216B2/en active Active
-
2020
- 2020-08-28 CY CY20201100809T patent/CY1123290T1/el unknown
- 2020-08-31 HR HRP20201384TT patent/HRP20201384T1/hr unknown
-
2021
- 2021-05-22 US US17/327,705 patent/US11702401B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286316A (en) | New micro-dystrophins and related method of use | |
IL276946A (en) | Antiproliferative compounds and methods of use | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
IL251988A0 (en) | Compounds acting on glycans and methods of using them | |
HRP20190432T1 (hr) | Spojevi pladienolid piridina i postupci uporabe | |
HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
LT3089971T (lt) | Junginiai ir panaudojimo būdai | |
SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
ZA201606450B (en) | Compounds and their methods of use | |
HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
GB201403697D0 (en) | Compounds and methods of use | |
GB201416797D0 (en) | Contianer and method of use thereof |